MRI and CSF studies in the early diagnosis of Alzheimer's disease

Abstract

The main goal of our studies has been to use MRI, FDG-PET, and CSF biomarkers to identify in cognitively normal elderly (NL) subjects and in patients with mild cognitive impairment (MCI), the earliest clinically detectable evidence for brain changes due to Alzheimer's disease (AD). A second goal has been to describe the cross-sectional and longitudinal interrelationships amongst anatomical, CSF and cognition measures in these patient groups. It is now well known that MRI-determined hippocampal atrophy predicts the conversion from MCI to AD. In our summarized studies, we show that the conversion of NL subjects to MCI can also be predicted by reduced entorhinal cortex (EC) glucose metabolism, and by the rate of medial temporal lobe atrophy as determined by a semi-automated regional boundary shift analysis (BSA-R). However, whilst atrophy rates are predictive under research conditions, they are not specific for AD and cannot be used as primary evidence for AD. Consequently, we will also review our effort to improve the diagnostic specificity by evaluating the use of CSF biomarkers and to evaluate their performance in combination with neuroimaging. Neuropathology studies of normal ageing and MCI identify the hippocampal formation as an early locus of neuronal damage, tau protein pathology, elevated isoprostane levels, and deposition of amyloid beta 1-42 (Ab42). Many CSF studies of MCI and AD report elevated T-tau levels (a marker of neuronal damage) and reduced Ab42 levels (possibly due to increased plaque sequestration). However, CSF T-tau and Ab42 level elevations may not be specific to AD. Elevated isoprostane levels are also reported in AD and MCI but these too are not specific for AD. Importantly, it has been recently observed that CSF levels of P-tau, tau hyperphosphorylated at threonine 231 (P-tau231) are uniquely elevated in AD and elevations found in MCI are useful in predicting the conversion to AD. In our current MCI studies, we are examining the hypothesis that elevations in P-tau231 are accurate and specific indicators of AD-related changes in brain and cognition. In cross-section and longitudinally, our results show that evaluations of the P-tau231 level are highly correlated with reductions in the MRI hippocampal volume and by using CSF and MRI measures together one improves the separation of NL and MCI. The data suggests that by combining MRI and CSF measures, an early (sensitive) and more specific diagnosis of AD is at hand. Numerous studies show that neither T-tau nor P-tauX (X refers to all hyper-phosphorylation site assays) levels are sensitive to the longitudinal progression of AD. The explanation for the failure to observe longitudinal changes is not known. One possibility is that brainderived proteins are diluted in the CSF compartment. We recently used MRI to estimate ventricular CSF volume and demonstrated that an MRI-based adjustment for CSF volume dilution enables detection of a diagnostically useful longitudinal P-tau231 elevation. Curiously, our most recent data show that the CSF isopros...

Episodic autobiographical memory in amnestic mild cognitive impairment: What are the neural correlates?

“…Patients with aMCI showed significantly reduced metabolic activity in the posterior cingulate cortex mainly (MNI coordinates: x = 6, y = -56, z = 26, Z = 4.11, k = 574, p FWE-corrected < .065 at cluster level), and in a small cluster in the right superior parietal lobule (x = 42, y = -62, z = 52, Z = 3.29, k = 35, p < .001 uncorrected at voxel level). Posterior cingulate hypometabolism and hippocampal atrophy form the typical pattern of brain changes associated with MCI (Chételat et al, 2003;Chételat et al, 2002;de Leon et al, 2004;Guedj et al, 2009;Masdeu et al, 2005;Stoub et al, 2006).…”

Neuropathological quantification of dtg APP/PS1: neuroimaging, stereology, and biochemistry

“…Stereological and neurochemical studies of brain tissue from patients with AD have confirmed widespread astrocytosis and microgliosis in cortical brain regions and significant reductions in neurotransmitter-specific subcortical nuclei, including the locus coeruleus (LC) and dorsal raphe (DR), and diminished concentrations in their cortical projections of corresponding monoamine neurotransmitters, norepinephrine (NE) and 5-hydroxytrptamine (5-HT); in contrast, these parameters remain relatively stable in brains of persons that undergo normal (non-demented) brain aging (Aletrino et al 1992;Mouton et al 1994;Storga et al 1996;Zarow et al 2003;Tuppo and Arias 2005). The strongest correlations with dementia severity have been reported in the loss of cortical volume (atrophy), observed by either ante-mortem or post-mortem analyses, and the reduction in cortical synapses (de la Monte 1989;DeKosky and Scheff 1990;Terry et al 1991;Convit et al 1993;Jobst et al 1994;Stout et al 1996;Mouton et al 1998;Zarow et al 2003;de Leon et al 2004). Thus, the evidence to date indicates that, while the diagnosis of AD depends heavily on the presence of amyloid plaques in neocortical brain regions, the progression of AD dementia appears to correlate more closely with degeneration of subcortical neurotransmitter systems that project to cortex, cortical synapse loss, and reduction of cortical volumes.…”

Alzheimer’s Disease Therapeutic Approaches

“…Brain MRI can document the structural diseases and the regional frontotemporal dementia. In case of structural MRI, the findings include focal atrophy and white matter lesions [21]. As these findings are nonspecific, the hippocampal volumes are considered to be the focal findings of the AD patients, because the hippocampal volume decline in normal aging and provides an evident support to the AD patients [24].…”

“…The changes that occur in the neuritic plaques shows to be the major mark of extracellular amyloid deposition and also the NFTs which acquire the intracellular accumulation of tau protein which is seem to be hyperphosphorylated (Fig. 3) [21]. The AD and PD are associated with defective tau proteins which lack the stabilizing capacity of microtubules.…”